This article was originally published on this site
NEW YORK, July 18, 2017 /PRNewswire/ —
If you want a Stock Review on TEVA, ENDP, IONS or AMRN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com turns to the Drug Manufacturers space, which consists of establishments that are primarily engaged in one or more of the following: manufacturing biological and medical products; processing botanical drugs and herbs; isolating active medical principles from botanical drugs and herbs; and manufacturing pharmaceutical products intended for internal and external consumption. Under review are Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), Ionis Pharmaceuticals Inc. (NASDAQ: IONS), and Amarin Corp. PLC (NASDAQ: AMRN). Learn more about these stocks by downloading their comprehensive and free reports from DailyStockTracker.com member’s area at:
On Monday, shares in Petach Tikva, Israel headquartered Teva Pharmaceutical Industries Ltd saw a slight decline of 0.22%, ending the day at $31.83. The stock recorded a trading volume of 7.79 million shares. The Company’s shares have advanced 4.60% in the last one month. The stock is trading above its 50-day moving average by 3.21%. Moreover, shares of Teva Pharma, which develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide, have a Relative Strength Index (RSI) of 50.78.
On July 13th, 2017, Teva Pharma announced that all proposals were approved at its Annual General Meeting of Shareholders held earlier that day. Shareholders voted to approve the elections of Murray Goldberg, Roberto Mignone, Dr. Perry Nisen, and Nechemia Peres to the Company’s Board of Directors.
On July 17th, 2017, research firm RBC Capital Markets reiterated its ‘Outperform’ rating on the Company’s stock with a decrease of the target price from $38 a share to $37 a share. TEVA complete research report is just a click away at:
Shares in Dublin, Ireland headquartered Endo International PLC ended the day 2.50% higher at $12.29 with a total trading volume of 3.77 million shares. In the last month and the previous three months, the stock has gained 13.80% and 14.43%, respectively. The Company’s shares are trading above their 50-day moving average by 2.25%. Furthermore, shares of Endo, which develops, manufactures, and distributes pharmaceutical products and devices worldwide, have an RSI of 59.61.
On July 14th, 2017, Endo announced that it will release its Q2 2017 financial results on August 08th, 2017. Members of the senior management team will host a conference call and webcast before the US financial markets open at 8:30 a.m. ET that same day. A simultaneous webcast of the call can be accessed on the Company’s website. The complimentary report on ENDP can be downloaded at:
At the close of trading on Monday, shares in Carlsbad, California headquartered Ionis Pharmaceuticals Inc. finished 2.73% higher at $53.01 with a total trading volume of 1.06 million shares. The stock has advanced 5.49% in the last one month, 25.74% over the previous three months, and 10.83% on an YTD basis. The Company’s shares are trading above their 50-day and 200-day moving averages by 7.71% and 20.58%, respectively. Additionally, shares of Ionis Pharma, which focuses on developing drugs for patients with severe and rare diseases, have an RSI of 56.76.
On July 13th, 2017, Akcea Therapeutics, Inc., a subsidiary of Ionis Pharmaceuticals, announced the pricing of its initial public offering of 15,625,000 shares common stock at a public offering price of $8.00 per share, for gross proceeds of $125.0 million before underwriting discounts and commissions and offering expenses to be paid by the Company. The offering is expected to close on July 19th, 2017, subject to customary closing conditions. Sign up for your complimentary research report on IONS at:
Dublin, Ireland-based Amarin Corp. PLC’s shares recorded a trading volume of 4.69 million shares at the end of yesterday’s session, which was above their three months average volume of 2.13 million shares. The stock closed the day 2.88% higher at $4.29. The Company’s shares have surged 45.42% in the past month, 36.62% in the previous three months, and 39.29% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 30.83% and 34.13%, respectively. Additionally, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 77.47.
On June 27th, 2017, research firm Cantor Fitzgerald resumed its ‘Overweight’ rating on the Company’s stock. Get free access to your research report on AMRN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you‘re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207) 331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA